Fundraising Fox
Peytant
Plymouth, US · Founded 2019 · Minnesota corporation · 12 employees on LinkedIn · 1 known investors
Find your way into Peytant
Sign up to see every warm intro you have to Peytant
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Peytant team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Peytant develops amnion-derived membrane coverings using human placental tissue to reduce the body's foreign body response in implants used for luminal disease treatment. The company's products are designed to increase patency and help clinicians manage vascular and other luminal conditions.
Founders & leadership
Peytant was founded in 2019 by John Schorgl and Steve Healy.
JS
John SchorglFounder & Executive Chairman
SH
Steve HealyFounder & DirectorSteve Healy has held senior leadership positions in medical device companies for over three decades, with expertise in regulatory compliance, quality assurance, and reimbursement strategy. He is the founder and director of Peytant, which develops amnion-derived membrane coverings to improve outcomes in implants used for vascular and luminal disease treatment.
JN
James NessExecutive
Board
JC
Jeffrey ChambersBoard director
BF
Bruce FaulkenBoard director
CW
Craig WalkerBoard director
CA
Clay AnselmoBoard director
Investors · 1
Relevance Ventureslisted by Relevance VenturesBrentwood · $250K – $2.5M
How we know: Relevance Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$4.9M disclosed across 4 rounds · 2015–2023
▶$2.9MraisedJan 2025 · 19 investors · BiotechnologyRule 506(b)
▶$2.9MraisedJan 2025 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SchorglExecutive Officer, Director, Promoter
- Bruce FaulkenDirector
- Craig WalkerDirector
- Steven HealyDirector
- Clay AnselmoDirector
- Offering amount
- $5M
- Amount sold
- $2.9M
- First sale
- Feb 2023
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$275KraisedMar 2021 · 3 investors · Other Health CareRule 506(b)
▶$275KraisedMar 2021 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John SchorglExecutive Officer
- Steven J. HealyDirector
- Craig WalkerDirector
- Jeffrey ChambersDirector
- Bruce FaulkenDirector
- Clay AnselmoDirector
- Offering amount
- $2M
- Amount sold
- $275K
- Minimum investment
- $3
- Proceeds to insiders
- $150K
- First sale
- Mar 2021
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$1.2MraisedOct 2017 · 11 investors · Other Health CareRule 506(b)
▶$1.2MraisedOct 2017 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Steven HealyDirector
- John SchorglExecutive Officer, Director
- Clay AnselmoDirector
- Jeffrey ChambersDirector
- Bruce FaulkenDirector
- Offering amount
- $4M
- Amount sold
- $1.2M
- First sale
- Jul 2017
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$576.5KraisedSep 2015 · 8 investors · Other Health CareRule 506(b)
▶$576.5KraisedSep 2015 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James NessExecutive Officer
- Jeffrey ChambersDirector
- John SchorglExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $576.5K
- Sales commissions
- $14.4K
- Placement agents
- Dougherty & Company LLC
- First sale
- Aug 2015
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Signant HealthSignant Health provides software platforms and clinical trial solutions for life sciences companies to manage patient-reported outcomes, evidence generation, and digital endpoints in drug development programs across multiple therapeutic areas.
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Companies working in the same space as Peytant.
In the news
Frequently asked questions
- What does Peytant do?
- Peytant develops amnion-derived membrane coverings using human placental tissue to reduce the body's foreign body response in implants used for luminal disease treatment. The company's products are designed to increase patency and help clinicians manage vascular and other luminal conditions.
- Who founded Peytant?
- Peytant was founded by John Schorgl, Steve Healy in 2019.
- Who are Peytant's investors?
- Peytant's investors include Relevance Ventures.
- How much funding has Peytant raised?
- Peytant has disclosed $4.9M raised across 4 rounds.
- Where is Peytant headquartered?
- Peytant is headquartered in Plymouth, US.